AI assistant
Sending…
Apellis Pharmaceuticals, Inc. — Director's Dealing 2021
Feb 11, 2021
31417_dirs_2021-02-11_7883f792-354b-495c-beb0-337231a81875.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-02-10
Reporting Person: Francois Cedric (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-10 | Common Stock | F | 2523 | $47.72 | Disposed | 1219833 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 234411 | Indirect |
Footnotes
F1: This represents shares withheld for tax on a restricted stock unit release.
F2: The securities are held by The Francois-DuBois Educational Trust (the "Trust"), for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
More from Apellis Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 14
Share Issue/Capital Change
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 14